Nutra Pharma unit to offer CR services

Florida, USA-based biotechnology firm Nutra Pharma, which is developing treatments for adrenomyeloneuropathy, HIV and multiple sclerosis, says  that its wholly-owned drug discovery subsidiary, ReceptoPharm, has  introduced a line of specialized contract research services aimed at  the early-stage life science market.

"As a clinical-stage company specializing in biologics, we understand  and have cleared many of the hurdles that face emerging biotech  companies," commented Paul Reid, chief executive of ReceptoPharm. "This  knowledge, combined with our qualified drug production facility, allows  us to leverage our expertise and capabilities by extending them to small  and start-up biotechnology companies looking for cost-effective  outsourcing solutions for their clinical development projects," he  added.

ReceptoPharm's services include pre-production studies, contract  manufacturing, US and European Union regulatory support and quality  systems, as well as Good Manufacturing Practice certification.  Additionally, the company can prepare and sterile fill pharmaceutical  products in its ISO class 5 cleanroom facilities for trials in the USA  and the EU.